Will the Phase 2 trial "Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder" reach primary completion on or before Sep 30, 2027?

Resolves Yes if ClinicalTrials.gov record NCT06651177 (T. John Winhusen, PhD) shows an actual primary completion date on or before Sep 30, 2027. Registered date at generation: Sep 30, 2027.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By Sep 30, 2027, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.